EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna

View source ↗

Summary

EMA recommends non-renewal of authorisation for Translarna (ataluren) for Duchenne muscular dystrophy, effectively ending its marketing authorisation in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)